aTyr Pharma, Inc.
NASDAQ:ATYRBiotechnology
+$0.07 today
- Market cap
- $52.13M
- Beta
- 0.54
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$0.71
Volume 1.02M
Average 2.29M
ATYR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
aTyr Pharma, Inc.NASDAQ: ATYR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $7.32M fell 38.1% year over year, behind the +5.5% change in trailing-twelve-month research & development. Sequentially, it fell 32.8% from the prior quarter. Over 3 fiscal years it compounded at +12.0% a year.
Context
- Research & development amounted to 31694.2% of revenue in FY2025, up 8557.2 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -38.1% toward the trailing-twelve-month pace of +5.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 60.22M USD
- Year-over-year change
- +10.8%
- 4-year CAGR
- +26.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.22M | +10.8% |
| FY2024 | 2024-12-31 | 54.37M | +28.6% |
| FY2023 | 2023-12-31 | 42.29M | -1.2% |
| FY2022 | 2022-12-31 | 42.81M | +84.0% |
| FY2021 | 2021-12-31 | 23.26M | — |
Research & Development vs competitors
How ATYR compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.5% is the highest of 8, against a peer median of -11.8%.
- Research & development amounts to 29327.4% of revenue for ATYR, versus a peer median of 118.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $66.71M USD | -38.5% | -7.9% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59.66M USD | -11.8% | +35.8% | — |
| LTM Mar 2026 | $55.72M USD | +5.5% | +12.0% | 29327.4% | |
| LTM Mar 2026 | $53.36M USD | -10.8% | +5.5% | 118.4% | |
| LTM Mar 2026 | $37.7M USD | -3.9% | — | 958.2% | |
| LTM Mar 2026 | $23.02M USD | -48.6% | -81.3% | — | |
| LTM Mar 2026 | $8.57M USD | -44.2% | -9.8% | — | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$4.56M CAD | +1.7% | -13.6% | 24.8% |
| Peer median (excluding ATYR) | — | -11.8% | -8.8% | 118.4% | |
Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 10.39M | 353K | 235K | 190K |
| Cost of Revenue | 1.3M | 1.7M | 0 | 0 | 1.55M |
| Gross Profit | (1.3M) | 8.69M | 353K | 235K | (1.36M) |
| Gross Margin | — | 83.7% | 100.0% | 100.0% | -717.4% |
| Research & Development | 23.26M | 42.81M | 42.29M | 54.37M | 60.22M |
| Selling, General & Admin | 10.75M | 12.29M | 12.98M | 13.78M | 17.6M |
| Operating Expenses | 32.71M | 55.1M | 55.27M | 68.15M | 76.26M |
| Depreciation & Amortization | 1.3M | 1.7M | 2.74M | 1.54M | 1.55M |
| EBITDA | (32.47M) | (43.65M) | (47.66M) | (62.48M) | (72.57M) |
| EBITDA Margin | — | -420.3% | -13500.3% | -26588.1% | -38192.1% |
| Operating Income | (34.02M) | (46.4M) | (54.92M) | (67.91M) | (77.63M) |
| Operating Margin | — | -446.8% | -15557.8% | -28899.6% | -40856.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 238K | 1.06M | 4.52M | 3.89M | 3.51M |
| Income Before Tax | (33.78M) | (45.34M) | (50.4M) | (64.02M) | (74.12M) |
| Pre-Tax Margin | — | -436.6% | -14276.8% | -27243.4% | -39009.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (33.77M) | (45.34M) | (50.39M) | (64.02M) | (74.12M) |
| Net Margin | — | -436.5% | -14274.5% | -27243.8% | -39009.5% |
| EPS (Basic) | (1.77) | (1.60) | (0.94) | (0.86) | (0.80) |
| EPS (Diluted) | (1.77) | (1.60) | (0.94) | (0.86) | (0.80) |
| Weighted Avg Shares | 19.08M | 28.42M | 53.61M | 74.26M | 92.99M |
| Weighted Avg Shares (Diluted) | 19.08M | 28.42M | 53.61M | 74.26M | 92.99M |
aTyr Pharma, Inc.
NASDAQ:ATYR
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.